Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of anti-PD-1/L1 (pembrolizumab, nivolumab, atezolizumab) plus anti-angiogenesis therapy (bevacizumab, anlotinib, apatinib) as a second-line or later therapy in patients with advanced non-small cell lung cancer: A retrospective cohort study

Next Previous
X
Search
Trial Profile

Efficacy and safety of anti-PD-1/L1 (pembrolizumab, nivolumab, atezolizumab) plus anti-angiogenesis therapy (bevacizumab, anlotinib, apatinib) as a second-line or later therapy in patients with advanced non-small cell lung cancer: A retrospective cohort study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Catequentinib (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Rivoceranib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 10 Mar 2021 New trial record
    • 01 Mar 2021 Results published in the Journal of Cancer Research and Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top